The Latest Breaking News from Baxter

Food safety watchdogs say product could contain undeclared allergen

As Baxter International prepares to report its fourth-quarter earnings next month, analysts expect a double-digit profit dip.

An IV fluid plant in North Carolina was hit by floodwaters and another now sits in the path of Hurricane Milton

Hospitals are calling on the Biden administration to take urgent action, including declaring a national emergency

Wayne Enterprises has curated a unique furniture collection inspired by Batman’s civilian persona. We find out what makes it all Bruce Wayne-worthy

Baxter has underperformed the healthcare sector over the past year, and analysts are cautious about the stock’s prospects.

The medtech industry’s long-term growth is fueled by growing demand for medical devices, adoption of cutting-edge technologies, and improved efficiency. Thus, it could be ideal to buy fundamentally solid medtech stocks Baxter International (BAX), Zimmer Biomet Holdings (ZBH), and Embecta (EMBC) poised for substantial growth. Keep reading.

Baxter stock tumbled Tuesday after the medtech company agreed to sell its kidney segment to Carlyle for $3.8 billion.

As Baxter International has underperformed the broader market over the past year, Wall Street analysts remain cautious about the stock's prospects.